Videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/the-continuum-of-care-for-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc@1x.jpg)
The Continuum of Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Maximizing Survival in Metastatic Hormone-Sensitive Prostate Cancer: The Role of Triplet Therapy - Kelvin Moses
- The Role of Urologists in Managing De Novo Metastatic Prostate Cancer - Benjamin Lowentritt
- Teamwork and Trust: Keys to Seamless Prostate Cancer Care Across Specialties - Paul Eber & Brad Somer View all The Continuum of Care for Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/state-of-the-art-interdisciplinary-management-of-prostate-cancer@1x.jpg)
State-of-the-Art Interdisciplinary Management of Prostate Cancer
- The Use of Radioligand Treatments in Metastatic Castration-Resistant Prostate Cancer - Matthew Abramowitz
- Case-Based Discussion on Navigating the Evolving Landscape of Castrate-Resistant Prostate Cancer Management - Oliver Sartor
- Advances in Staging and Personalized Radiation Therapy for High-Risk Localized Prostate Cancer - Leslie Ballas View all State-of-the-Art Interdisciplinary Management of Prostate Cancer videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/nccn-2024@1x.jpg)
NCCN 2024 Prostate Cancer Guidelines Update
- 2024 NCCN Guidelines: Managing Bone Health in Prostate Cancer Patients - Rashid Sayyid & Zachary Klaassen
- 2024 NCCN Guidelines: Preventing Skeletal Events in Prostate Cancer - Rashid Sayyid & Zachary Klaassen
- 2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment - Rashid Sayyid & Zachary Klaassen View all NCCN 2024 Prostate Cancer Guidelines Update videos
Featured Videos
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/endourology@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/health-policy-in-urological-diseases@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/bladder-cancer@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/esmo-2022@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/apccc-2022@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/localized-prostate-cancer@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/practical-aspects-of-radioligand-therapy-in-the-clinic@1x.jpg)
![](https://www.urotoday.com/templates/t3_bs3_blank/images/video-channels/advanced-prostate-cancer@1x.jpg)
Genomic Classifier in Prostate Cancer: High-Risk
High-Risk Non-Muscle Invasive Bladder Cancer
Advanced Bladder Cancer
Integrating (177Lu)–PSMA-617: A Practical Approach for Urology Clinics
Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC
APCCC 2024
Latest Videos
EMBARK
Recent Conference Coverage
![](https://www.urotoday.com/templates/t3_bs3_blank/images/conferences-images/bcantt-2024@2x.jpg)
- BCANTT 2024: Rationally Engineered IL2 for Enhanced Treatment of Local and Metastatic Bladder Cancer
- BCANTT 2024: Setting the Stage: BCG Unresponsive Disease
- BCANTT 2024: Dissecting the Impact of E-Cadherin Loss on the Immune Microenvironment
Recent Physician-Scientist Review Articles
![](https://www.urotoday.com/templates/t3_bs3_blank/images/physician-images/mhspc-coe@2x.jpg)
- Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Written by Zachary Klaassen, MD, MSc Associate Professor of Urology Urologic Oncologist Medical College of Georgia, Georgia Cancer Center Augusta, GA and Rashid Sayyid, MD, MSc Urologic Oncology Fellow University of Toronto Toronto, Ontario, Canada
- Prostate Radiotherapy for De Novo, Low Volume Metastatic Hormone Sensitive Prostate Cancer: Is There Benefit?
Written by Rashid Sayyid, MD, MSc and Zachary Klaassen, MD, MSc
![](https://www.urotoday.com/templates/t3_bs3_blank/images/physician-images/psma-targeted-therapy-coe@2x.jpg)
- Beyond a VISION to Making a SPLASH: Advances in PSMA-Based Theranostics in Prostate Cancer
Written by Zachary Klaassen, MD, MSc, Medical College of Georgia, Augusta, Georgia
Transformative Evidence
EMBARK Trial
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.Serum tumor markers can be a blessing and a curse. After definitive local therapy for prostate cancer, prostate-specific antigen (PSA) is quite sensitive and specific, and can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease. When biochemical recurrence (BCR) occurs, early detection can guide curative-intent salvage therapies such as salvage radiation.
Read MoreARASENS Trial
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.In the ARASENS trial (NCT02799602), darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel significantly reduced the risk of death by 32.5% (HR, 0.68; 95% CI, 0.57-0.80; P < .0001) compared with placebo plus ADT with docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC). We present efficacy and safety of darolutamide versus placebo in Black patients from ARASENS.
Read MoreTrials in Progress
CLARIFY Trial
Clarity receives FDA Fast Track Designation for 64Cu-SAR- bisPSMAPivot-006 Trial
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trialRead More